Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Shares of Gilead (Nasdaq: GILD) were gapping up Monday morning with an open price 11.2% higher than Friday's closing price. The stock closed at $65.01 Friday and opened today's trading at $72.31.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The average volume for Gilead has been seven million shares per day over the past 30 days. Gilead has a market cap of $49.13 billion and is part of the health care sector and drugs industry. Shares are up 58.4% year to date as of the close of trading on Friday. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. The company has a P/E ratio of 20.1, above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Gilead Ratings Report. Get more investment ideas from our investment research center. FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.